Stay updated on Trastuzumab Emtansine in HER2+ Tumors Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab Emtansine in HER2+ Tumors Clinical Trial page.

Latest updates to the Trastuzumab Emtansine in HER2+ Tumors Clinical Trial page
- Check6 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 from the revision history.SummaryDifference0.0%

- Check13 days agoChange DetectedLocation name updated from Padua to Padova for the Veneto, Italy site (35128).SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check35 days agoChange DetectedRevision label updated to v3.5.0 with the v3.4.3 label removed.SummaryDifference0.0%

- Check42 days agoChange DetectedRevision labels updated: v3.4.3 added and v3.4.2 removed.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision: v3.4.2 was added to the site, and the previous funding-status notice (v3.4.1) was removed.SummaryDifference0.4%

- Check77 days agoChange DetectedNew site-wide notice about lapse in government funding and NIH Clinical Center operations is now visible, and the page revision has been updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Trastuzumab Emtansine in HER2+ Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab Emtansine in HER2+ Tumors Clinical Trial page.